Table 1 Clinical characteristics and neuropsychological performance at baseline and through clinical follow-up at 6, 12 and 24 months from the baseline: comparison between fast decliners and slow decliners.
From: NFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline
Total (n = 40) | Fast declined (n = 20) | Slow declined (n = 20) | p | |
|---|---|---|---|---|
Age (years), mean (SD) | 78 (8) | 79 (9) | 77 (7) | 0.534 |
Male gender, n(%) | 10 (25%) | 4 (20%) | 6 (30%) | 0.465 |
Length of disease progression (years), median [range] | 2 [0–6] | 2 [0–6] | 3 [0–5] | 0.946 |
Symptomatic treatment of Alzheimer’s disease at baseline, n (%) | 29 (72%) | 15 (75%) | 14 (70%) | 0.723 |
MMS at baseline, mean (SD) | 21 (3) | 21 (2) | 21 (3) | 0.953 |
ADAScog at baseline, mean (SD) | 15 (6) | 17 (6) | 13 (5) | 0.058 |
MMS at 6-month follow-up, mean (SD) | 20 (4) | 20 (4) | 21 (4) | 0.161 |
ADAScog at 6-month follow-up, mean (SD) | 16 (8) | 20 (8) | 12 (4) | 0.0004 |
MMS at 12-month follow-up, mean (SD) | 20 (4) | 18 (4) | 22 (4) | 0.003 |
ADAScog at 12-month follow-up, mean (SD) | 18 (9) | 23 (9) | 13 (5) | 0.0003 |
MMS at 24-month follow-up, mean (SD) | 17 (5) | 14 (4) | 21 (3) | < 0.0001 |
ADAScog at 24-month follow-up, mean (SD) | 21 (12) | 28 (13) | 15 (6) | 0.0003 |
MMS decline (points)*, median [range] | − 4 [− 14; 3] | − 6 [− 14; − 4] | − 0.5 [− 4; 3] | < 0.0001 |
ADAScog decline (points)*, median [range] | 2.5 [− 5; 30] | 11 [− 5; 30] | − 0.1 [− 4; 11] | 0.0003 |
MMS relative decline (%)§, median [range] | − 19 [− 74; 16] | − 32 [− 74; − 18] | − 2 [− 23; 16] | < 0.0001 |
ADAScog relative decline (%)§, median [range] | 26 [− 29; 180] | 63 [− 17; 180] | − 0.8 [− 29; 116] | 0.007 |
